Skip to content
10-Q

Quarterly Report

NURIX THERAPEUTICS, INC. NRIX

0001549595-26-000025

← back to feed
Filed
Apr 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 1, 2026 103.41M sh
Shares Diluted Q1 2026 · Feb 28, 2026 110.07M sh
Shares Diluted Q1 2026 · Feb 28, 2025 83.56M sh
Capex Q1 2026 · Feb 28, 2026 $1.05M
Capex Q1 2026 · Feb 28, 2025 $3.49M
Operating Cash Flow Q1 2026 · Feb 28, 2026 −$71.91M
Operating Cash Flow Q1 2026 · Feb 28, 2025 −$61.09M
Cash And Equivalents Q1 2026 · Feb 28, 2026 $71.2M
Cash And Equivalents Q1 2026 · Nov 30, 2025 $246.96M
Cash And Equivalents Q1 2026 · Feb 28, 2025 $75.92M
Stockholders Equity Q1 2026 · Feb 28, 2026 $480.89M
Stockholders Equity Q1 2026 · Nov 30, 2025 $538.75M
Stockholders Equity Q1 2026 · Feb 28, 2025 $480.92M
Stockholders Equity Q1 2026 · Nov 30, 2024 $526.99M
Current Liabilities Q1 2026 · Feb 28, 2026 $92.2M
Current Liabilities Q1 2026 · Nov 30, 2025 $86.47M
Total Liabilities Q1 2026 · Feb 28, 2026 $155.24M
Total Liabilities Q1 2026 · Nov 30, 2025 $149.39M
Current Assets Q1 2026 · Feb 28, 2026 $554.39M
Current Assets Q1 2026 · Nov 30, 2025 $606.82M
Total Assets Q1 2026 · Feb 28, 2026 $636.13M
Total Assets Q1 2026 · Nov 30, 2025 $688.14M
Eps Diluted Q1 2026 · Feb 28, 2026 −$0.79
Eps Diluted Q1 2026 · Feb 28, 2025 −$0.67
Eps Basic Q1 2026 · Feb 28, 2026 −$0.79
Eps Basic Q1 2026 · Feb 28, 2025 −$0.67
Sga Expense Q1 2026 · Feb 28, 2026 $14.61M
Sga Expense Q1 2026 · Feb 28, 2025 $11.65M
Rd Expense Q1 2026 · Feb 28, 2026 $84.14M
Rd Expense Q1 2026 · Feb 28, 2025 $69.66M
Net Income Q1 2026 · Feb 28, 2026 −$87.17M
Net Income Q1 2026 · Feb 28, 2025 −$56.35M
Operating Income Q1 2026 · Feb 28, 2026 −$92.5M
Operating Income Q1 2026 · Feb 28, 2025 −$62.86M
Revenue Q1 2026 · Feb 28, 2026 $6.25M
Revenue Q1 2026 · Feb 28, 2025 $18.45M